Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). [electronic resource]
Producer: 20120306Description: 857-68 p. digitalISSN:- 1699-3993
- Anilides -- adverse effects
- Animals
- Antineoplastic Agents -- adverse effects
- Clinical Trials as Topic
- Drug Interactions
- Drugs, Investigational -- adverse effects
- Humans
- Neoplasms -- drug therapy
- Proto-Oncogene Mas
- Pyridines -- adverse effects
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.